Abstract
In an epidemic or pandemic caused by a pathogen that has never been encountered, scientists have to compete against time to develop new vaccines. Vaccination effectively prevents the spread of the disease and saves lives. Under the COVID-19 crisis, several types of vaccines were developed and authorized as Emergency Use Authorization (EUA), including the first mRNA vaccine product ever approved by FDA, the BNT162b1. The transiently expressed mRNA does not encounter the problem of genome integration with the host and it takes less time to develop, which differentiates it from alternative types such as inactivated and subunit vaccines. This paper attempts to present the difference of the BNT162b2 mRNA vaccine from the Novavax subunit vaccine, and the Sinovac inactivated vaccine, in terms of COVID-19 prevention and adverse events, therefore attempts to provide a better understanding of the behaviors of mRNA vaccines under COVID-19.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
